Blog

GISTs with PDGFRA mutation show lower 18F-FDG uptake compared to other molecular subtypes

mdanderson.org

Jan 27, 2025, 08:54

GISTs with PDGFRA mutation show lower 18F-FDG uptake compared to other molecular subtypes

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared an article by Maria Concetta Nigro on LinkedIn:

“GISTs with PDGFRA mutation show lower 18F-FDG uptake compared to other molecular subtypes, especially KIT exon 11–mutant GISTs JAMA Network Open.

Median SUVmax in D842V-mutant GISTs:

Median SUVmax in non-D842V-mutant GISTs: 3.6
• Median SUVmax in KIT exon 11-mutant GISTs: 10.1
• Clinical Relevance: Low FDG uptake in PDGFRA-mutant GISTs may limit the utility of FDG-PET in this subgroup but raises questions about its prognostic and predictive value.

Molecular Era Needs Molecular Imaging.”

18F-Fluorodeoxyglucose Uptake in ***PDGFRA*-Mutant Gastrointestinal Stromal Tumors.**

Authors: Maria Concetta Nigro, et al.

GISTs with PDGFRA mutation show lower 18F-FDG uptake compared to other molecular subtypes

cancer D842V Elvina Almuradova European Institute of Oncology fight against cancer Fluorodeoxyglucose Gastrointestinal Stromal Tumors GISTs Global fight against cancer JAMA Network Open molecular imaging OncoDaily Oncology PDGFRA mutation

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC